Cargando…

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype

The aim of this study was to compare the hemostatic efficacy of recombinant factor VIII Fc (rFVIIIFc) (Eloctate) and Advate by ex-vivo rotation thromboelastometry (ROTEM) of whole blood and to explore potential ROTEM parameters that may be more predictive of a patient's bleeding tendency than p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Driessler, Frank, Miguelino, Maricel G., Pierce, Glenn F., Peters, Robert T., Sommer, Jurg M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642334/ https://www.ncbi.nlm.nih.gov/pubmed/28486277 http://dx.doi.org/10.1097/MBC.0000000000000638

Ejemplares similares

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein
por: PETERS, R T, et al.
Publicado: (2013)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity
por: Buyue, Yang, et al.
Publicado: (2014)

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
por: Sommer, J M, et al.
Publicado: (2014)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Rotational thromboelastometry in critical phase of dengue infection: Association with bleeding
por: Wickramasinghe, Wasanthi, et al.
Publicado: (2022)

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
por: Georgescu, Maria T., et al.
Publicado: (2020)

Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B
por: Miguelino, Maricel G, et al.
Publicado: (2014)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Evaluation of Thromboelastometry in Sepsis in Correlation With Bleeding During Invasive Procedures
por: Lukas, Pavel, et al.
Publicado: (2017)

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes
por: van der Flier, Arjan, et al.
Publicado: (2015)

The role of evidence-based algorithms for rotational thromboelastometry-guided bleeding management
por: Görlinger, Klaus, et al.
Publicado: (2019)

Recombinant FIX Fc fusion protein activity assessment with the one‐stage clotting assay: A multicenter, assessor‐blinded, prospective study in Japan (J‐Field Study)
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
por: Giraud, Romain, et al.
Publicado: (2021)

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
por: Wang, Michael, et al.
Publicado: (2016)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

Rotational Thromboelastometry for Assessing Bleeding Complications and Factor XIII Deficiency in Cardiac Surgery Patients
por: Raspé, Christoph, et al.
Publicado: (2018)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Endogenous Heparinoids May Cause Bleeding in Mucor Infection and can be Detected by Nonactivated Thromboelastometry and Treated by Recombinant Activated Factor VII: A Case Report
por: Durila, Miroslav, et al.
Publicado: (2016)

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study
por: Malec, Lynn, et al.
Publicado: (2023)

Clinical value of early assessment of hyperfibrinolysis by rotational thromboelastometry during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands
por: Tahitu, Marije, et al.
Publicado: (2021)

Correlation of plasma coagulation tests and fibrinogen(Clauss) with rotational thromboelastometry parameters and prediction of bleeding in dogs
por: Enk, Nathalie M., et al.
Publicado: (2018)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Investigation of predictors of bleeding complications in COVID‐19 using rotational thromboelastometry (ROTEM(Ⓡ)): A retrospective study
por: Matsuoka, Ayaka, et al.
Publicado: (2022)

A new era of thromboelastometry
por: Crochemore, Tomaz, et al.
Publicado: (2017)

Real‐world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples
por: Sommer, Jurg M., et al.
Publicado: (2020)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Acquired Factor VIII Inhibitor Presenting as Occult GI Bleeding
por: Pacheco Cano, Carlos I., et al.
Publicado: (2018)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa
por: Kannicht, Christoph, et al.
Publicado: (2020)

Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein
por: McCue, J, et al.
Publicado: (2014)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
por: Zerra, Patricia E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g2qn8hbrr8otglkib0st6soeo6